Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)
Conditions
Interventions
Dulaglutide
Oral antihyperglycemics
Locations
44
Japan
Nakayama Clinic
Nagoya, Aichi-ken, Japan
Tosaki Clinic for Diabetes and Endocrinology
Nagoya, Aichi-ken, Japan
Kashiwa City Hospital
Kashiwa, Chiba, Japan
Kobari General Clinic
Noda, Chiba, Japan
Nippon Kokan Fukuyama Hospital
Fukuyama-shi, Hiroshima, Japan
Yamagata Naika Clinic
Asahikawa, Hokkaido, Japan
Start Date
April 13, 2021
Primary Completion Date
October 1, 2022
Completion Date
April 26, 2023
Last Updated
May 22, 2024
NCT07051005
NCT00001987
NCT07480161
NCT04786262
NCT06748963
NCT06887049
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions